Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism

G. Vita, A. Toscano, G. Mileto, F. Pilrone, M. T. Ferro, E. Gagliardi, N. Bresolin, F. Fortunalo, C. Messina

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A 58-year-old man with chronic renal failure developed severe muscle pain and tenderness I week after starting bezafibrate 400 mg daily. Serum creatine kinase was 32,280 U/l. Muscle biopsy revealed scattered necrotic fibers and mild type 2b atrophy. Muscle total and free carnitine were at the upper limits of the normal range. Biochemical investigations of muscle homogenate showed normal carnitine pelmityl transferase (CPT) as well as normal individual glycolytic and mitochondrial enzyme activities. Withdrawal of the drug was followed by rapid clinical improvement. Our study casts doubt on the hypothesis that bezafibrate is able to affect muscle metabolic pathways. It is likely that the drug acts on cholesterol constituents of the muscle membrane. producing discontinuities of the sarcolemma and initiating cell necrosis.

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalEuropean Neurology
Volume33
Issue number2
DOIs
Publication statusPublished - 1993

Fingerprint

Bezafibrate
Muscular Diseases
Muscles
Carnitine
Myalgia
Sarcolemma
Creatine Kinase
Transferases
Metabolic Networks and Pathways
Pharmaceutical Preparations
Chronic Kidney Failure
Atrophy
Reference Values
Necrosis
Cholesterol
Biopsy
Membranes
Enzymes
Serum

Keywords

  • Bezafibrate
  • Myopathy
  • Renal failure
  • Rhabdomyolysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Vita, G., Toscano, A., Mileto, G., Pilrone, F., Ferro, M. T., Gagliardi, E., ... Messina, C. (1993). Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism. European Neurology, 33(2), 168-172. https://doi.org/10.1159/000116927

Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism. / Vita, G.; Toscano, A.; Mileto, G.; Pilrone, F.; Ferro, M. T.; Gagliardi, E.; Bresolin, N.; Fortunalo, F.; Messina, C.

In: European Neurology, Vol. 33, No. 2, 1993, p. 168-172.

Research output: Contribution to journalArticle

Vita, G, Toscano, A, Mileto, G, Pilrone, F, Ferro, MT, Gagliardi, E, Bresolin, N, Fortunalo, F & Messina, C 1993, 'Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism', European Neurology, vol. 33, no. 2, pp. 168-172. https://doi.org/10.1159/000116927
Vita G, Toscano A, Mileto G, Pilrone F, Ferro MT, Gagliardi E et al. Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism. European Neurology. 1993;33(2):168-172. https://doi.org/10.1159/000116927
Vita, G. ; Toscano, A. ; Mileto, G. ; Pilrone, F. ; Ferro, M. T. ; Gagliardi, E. ; Bresolin, N. ; Fortunalo, F. ; Messina, C. / Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism. In: European Neurology. 1993 ; Vol. 33, No. 2. pp. 168-172.
@article{09ffa57aa1b24c0b9e0db223ec8cb8a2,
title = "Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism",
abstract = "A 58-year-old man with chronic renal failure developed severe muscle pain and tenderness I week after starting bezafibrate 400 mg daily. Serum creatine kinase was 32,280 U/l. Muscle biopsy revealed scattered necrotic fibers and mild type 2b atrophy. Muscle total and free carnitine were at the upper limits of the normal range. Biochemical investigations of muscle homogenate showed normal carnitine pelmityl transferase (CPT) as well as normal individual glycolytic and mitochondrial enzyme activities. Withdrawal of the drug was followed by rapid clinical improvement. Our study casts doubt on the hypothesis that bezafibrate is able to affect muscle metabolic pathways. It is likely that the drug acts on cholesterol constituents of the muscle membrane. producing discontinuities of the sarcolemma and initiating cell necrosis.",
keywords = "Bezafibrate, Myopathy, Renal failure, Rhabdomyolysis",
author = "G. Vita and A. Toscano and G. Mileto and F. Pilrone and Ferro, {M. T.} and E. Gagliardi and N. Bresolin and F. Fortunalo and C. Messina",
year = "1993",
doi = "10.1159/000116927",
language = "English",
volume = "33",
pages = "168--172",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Bezafibrate-lnduced myopathy no evidence for defects in muscle metabolism

AU - Vita, G.

AU - Toscano, A.

AU - Mileto, G.

AU - Pilrone, F.

AU - Ferro, M. T.

AU - Gagliardi, E.

AU - Bresolin, N.

AU - Fortunalo, F.

AU - Messina, C.

PY - 1993

Y1 - 1993

N2 - A 58-year-old man with chronic renal failure developed severe muscle pain and tenderness I week after starting bezafibrate 400 mg daily. Serum creatine kinase was 32,280 U/l. Muscle biopsy revealed scattered necrotic fibers and mild type 2b atrophy. Muscle total and free carnitine were at the upper limits of the normal range. Biochemical investigations of muscle homogenate showed normal carnitine pelmityl transferase (CPT) as well as normal individual glycolytic and mitochondrial enzyme activities. Withdrawal of the drug was followed by rapid clinical improvement. Our study casts doubt on the hypothesis that bezafibrate is able to affect muscle metabolic pathways. It is likely that the drug acts on cholesterol constituents of the muscle membrane. producing discontinuities of the sarcolemma and initiating cell necrosis.

AB - A 58-year-old man with chronic renal failure developed severe muscle pain and tenderness I week after starting bezafibrate 400 mg daily. Serum creatine kinase was 32,280 U/l. Muscle biopsy revealed scattered necrotic fibers and mild type 2b atrophy. Muscle total and free carnitine were at the upper limits of the normal range. Biochemical investigations of muscle homogenate showed normal carnitine pelmityl transferase (CPT) as well as normal individual glycolytic and mitochondrial enzyme activities. Withdrawal of the drug was followed by rapid clinical improvement. Our study casts doubt on the hypothesis that bezafibrate is able to affect muscle metabolic pathways. It is likely that the drug acts on cholesterol constituents of the muscle membrane. producing discontinuities of the sarcolemma and initiating cell necrosis.

KW - Bezafibrate

KW - Myopathy

KW - Renal failure

KW - Rhabdomyolysis

UR - http://www.scopus.com/inward/record.url?scp=0027469847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027469847&partnerID=8YFLogxK

U2 - 10.1159/000116927

DO - 10.1159/000116927

M3 - Article

C2 - 8467827

AN - SCOPUS:0027469847

VL - 33

SP - 168

EP - 172

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 2

ER -